Alzheimer Disease

Expert Nikhil Palekar, MD, said that although the treatment is far from a cure, it is a vital first step toward other treatments for Alzheimer Disease.

Lecanemab-irmb is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer disease.

To slow the production of MCI and dementia, utilizing more ways of establishing the diagnoses for women can prevent the progression.

Utilizing longitudinal assessments of language impairment and clinical progression could help identify challenges earlier.

Leqembi is an intravenous injection for the treatment of Alzheimer disease.

Brexpiprazole was associated with a statistically and clinically meaningful improvement in agitative behaviors caused by dementia compared to placebo.

Lack of awareness, or anosognosia, may be present up to 2 to 3 years before an Alzheimer dementia diagnosis is made.

More than half of patients with Alzheimer disease administered donanemab showed a significantly reduced cognitive and functional decline.

As more drugs gain coverage, decision-makers will need to more accurately diagnose Alzheimer disease, especially in the community setting.

Strong interprofessional team helps ensure safe transitions and minimize adverse events, medication errors

Perceived stress and cognitive performance are independently associated. Stress can also increase the risk of worsening cognition.

Eli Lilly treatment targets soluble amyloid beta and did not clear plaque or halt accumulation of amyloid in individuals treated with the drug in the A4 study.

Investigators noted medication prescription disparities among patients with dementia despite factoring for age and sex.

Low cognitive functioning and cognitive decline have been linked to an increased risk of morbidity and mortality.

Promising results for lecanemab's efficacy in patients with mild cognitive impairment or mild dementia associated with Alzheimer disease were accompanied by reports of adverse effects associated with treatment.

The model can predict the chronological ages of cognitively normal participants with an average absolute error of 2.3 years, which is about 1 year more accurate than an existing model.

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

Lecanemab (Lequembi) approved to treat mild cognitive impairment or mild dementia associated with Alzheimer disease.

Indication can play a major role in pharmacists recommending brain health products.

White adults in their midlife showed slower brain aging than Black and Latinx individuals, but between mid- and late life, they showed increased signs of aging.

Legislation expands protection of original 1965 act to individuals younger than 60 years.

Patients with Alzheimer disease administered gantenerumab did experience slower clinical decline, however, it was not deemed statistically significant.

Eisai plans to file for traditional approval in the United States by March 31, 2023.

Tacrine was originally brought to the market in 1993 as an acetylcholinesterase inhibitor to fight the symptoms of Alzheimer disease.

Patients with type 2 diabetes may lower their risk of developing severe neurological disorders like Alzheimer disease by taking certain anti-diabetic medications alongside daily insulin.